Dewpoint Therapeutics obtains $150M in series C financing
Dewpoint Therapeutics, a company focused on developing medications to treat diseases resulting from the dysregulation of biomolecular condensates, has raised $150 million in series C financing. Read More
CRISPR Therapeutics, ViaCyte dose type 1 diabetes patient with new cell therapy
CRISPR Therapeutics and ViaCyte have dosed the first patient with VCTX210 in a phase I clinical trial for the treatment of type 1 diabetes. Read More
Intellia Therapeutics acquires Rewrite Therapeutics
Intellia Therapeutics has acquired Rewrite Therapeutics, a private biotechnology company focused on advancing novel DNA writing technologies. The acquisition further expands Intellia's genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR-Cas9 and base editing technologies. Read More
Tierra Biosciences launches online protein ordering
Tierra Biosciences has launched the Tierra Protein platform, an e-commerce portal that allows customers to have custom proteins synthesized, validated, and shipped to them. Read More
DNA Script joins Wellcome Leap R3 program
DNA Script has inked a multimillion-dollar, multiyear contract with Wellcome Leap to accelerate RNA products, including mRNA vaccines, and advance RNA therapies. Under Wellcome Leap's RNA Response + Readiness (R3) program, DNA Script will develop a fully automated, deployable system to synthesize DNA templates for RNA production with a short turnaround time. Read More
Avidien Technologies nabs $4M for its liquid handling products
Avidien has received a new financing round of $4 million from BroadOak Capital Partners. The investment will help Avidien expand its product road map, scale commercial production, and better serve research and pharmaceutical clients. Read More
Mission Bio transfers 1st Tapestri GMP-ready CGT assay
Mission Bio has completed the first tech transfer of a clinical trial-, good manufacturing practices (GMP)-ready cell and gene therapy (CGT) assay from its Tapestri platform to Avance Biosciences, to assess transduction efficiency for an autologous cell therapy currently under development. Read More
SQZ Biotechnologies reveals preclinical data on immune cell engineering advances
SQZ Biotechnologies published preclinical research on the company's ability to engineer multiple immune cell types to drive major histocompatibility class I antigen presentation -- a critical advance in the ability to drive a patient's killer T cells to fight multiple diseases -- in the Journal of Immunology. Read More
Waters acquires charge detection mass spectrometry assets
Waters has acquired the technology assets and intellectual property rights of Megadalton Solutions, an early-stage developer of charge detection mass spectrometry technology and services. Read More
KromaTiD launches cell culture services
KromaTiD has launched of a suite of cell and blood culture growth, isolation, processing, and quality control services. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
